Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region

Gene Therapy

Volumn 8, Issue 15, 2001, Pages 1142-1148

  Hawkins, L K ^a,b   Hermiston, T ^a,c  

^a ONYX PHARMACEUTICALS   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c BAYER AG   (Germany)

Author keywords

Adenovirus; Armed therapeutic virus; E3 region; Gene delivery; Oncolytic; Replication selective

Indexed keywords

ANTINEOPLASTIC AGENT; ONYX 015; ONYX 321; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; CYTOSINE DEAMINASE; ONYX 300; ONYX 305; ONYX 320; RESTRICTION ENDONUCLEASE; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL CELL; ARTICLE; BIOLOGY; CANCER THERAPY; CONTROLLED STUDY; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; RNA SPLICING; TRANSGENE; TUMOR; VIRUS REPLICATION; CELL VIABILITY; DNA MODIFICATION; DRUG EFFICACY; GENE DELETION; GENE EXPRESSION REGULATION; LYSIS; MULTIGENE FAMILY; PREDICTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS INFECTION;

ADENOVIRUS E3 PROTEINS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NEOPLASMS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION; ADENOSINE DIPHOSPHATE; ADENOVIRUSES, HUMAN; CYTOSINE DEAMINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE DELETION; NUCLEOSIDE DEAMINASES;

EID: 0034893340     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301509     Document Type: Article

References (44)

1. Replication-selective adenoviruses as oncolytic agents
2. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
3. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
4. ONYX-015: Clinical data are encouraging
5. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
6. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
7. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
8. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K/gp19 K region
9. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region
10. Adenovirus E3 proteins: 14.7 K, RID, and gp19 K inhibit immune-induced cell death: Adenovirus death protein promotes cell death
11. Structurally related class I and class II receptor protein tyrosine kinases are down-regulated by the same E3 protein coded for by human group C adenoviruses
12. Epidermal growth factor receptor is down-regulated by a 10, 400 MW protein encoded by the E3 region of adenovirus
13. Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis
14. Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers
15. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains
16. Effect of tumour necrosis factor on cultured human melanoma cells
17. An endotoxin-induced serum factor that causes necrosis of tumors
18. Tumor necrosis factor (TNF) alpha: Control of TNF-sensitivity and molecular mechanisms of TNF-mediated growth inhibition
19. Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies
20. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats
21. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
22. Limb desmoid tumors: A possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan
23. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation
24. Recombinant human tumor necrosis factor-alpha: Thrombus formation is a cause of anti-tumor activity
25. In vitro remodeling of tumor vascular endothelial cells using conditioned medium from various tumor cells and their sensitivity to TNF-alpha
26. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma
27. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: Observations in patients and preclinical perfusion models
28. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer
29. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor
30. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat
31. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: A new anti-tumour approach
32. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation
33. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis
34. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
35. DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309
36. Down-regulation of human adenovirus E1a by E3 products: Evidence for translational control of E1a by E3 14.5 K and/or E3 10.4 K products
37. Packaging capacity and stability of human adenovirus type 5 vectors
38. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
39. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
40. The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
41. TNF-induced activation of NF-kappa B
42. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-kappa B. TNF alpha is not needed for induction of effect via TNF receptors
43. Lymphoid specific gene expression of the adenovirus early region 3 promoter is mediated by NF-kappa B binding motifs
44. E3 transcription unit of adenovirus